Tilray (NASDAQ:TLRY – Get Free Report) released its earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06), Zacks reports. The business had revenue of $185.78 million during the quarter, compared to the consensus estimate of $213.38 million. Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. Tilray updated its FY 2025 guidance to EPS.
Tilray Price Performance
Shares of TLRY opened at $0.46 on Wednesday. The firm has a market capitalization of $427.85 million, a PE ratio of -1.52 and a beta of 1.88. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. The company’s 50-day moving average is $0.77 and its 200-day moving average is $1.20. Tilray has a fifty-two week low of $0.45 and a fifty-two week high of $2.52.
Analyst Ratings Changes
Separately, Canaccord Genuity Group raised their price target on Tilray from $2.00 to $3.00 and gave the stock a “buy” rating in a research note on Monday, January 13th.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
See Also
- Five stocks we like better than Tilray
- Financial Services Stocks Investing
- Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder?
- What is the Nikkei 225 index?
- Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play?
- What is Insider Trading? What You Can Learn from Insider Trading
- Make Big Bets on Gold With These 3 Leveraged Mining Funds
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.
